Akums Subsidiary Receives ₹52.7 Crore Demand Notice from NPPA
Akums' subsidiary, Pure and Cure Healthcare, received a ₹52.75 crore demand notice from NPPA regarding 'Lanol 1000 mg injection'. The notice alleges exceeding MRP limits. The total impact includes overcharging (₹18.95 crore), penalty (₹18.95 crore), and interest (₹14.85 crore) up to Oct 30, 2026. Hetero Healthcare is primarily responsible for response.
The demand notice involves a substantial monetary amount of over ₹52 crore, including penalties and interest, which could significantly impact the company's financial performance.
The company's subsidiary has received a significant demand notice from a regulatory authority, indicating a potential financial liability and operational risk.
Akums Drugs and Pharmaceuticals Limited has announced that its wholly-owned subsidiary, Pure and Cure Healthcare Private Limited, has received a Demand Notice from the National Pharmaceutical Pricing Authority (NPPA). The notice, dated October 13, 2026, pertains to the manufacturing of the formulation “Lanol 1000 mg injection” 100ml for Hetero Healthcare Limited.
The NPPA alleges that the Maximum Retail Price (MRP) fixed for the product exceeded the limits prescribed under The Drugs (Prices Control) Order, 2013. The demand notice was issued to three parties: Hetero Healthcare Limited (Marketer), Abaris Healthcare Private Limited, and Pure & Cure Healthcare Private Limited (Manufacturer).
Akums stated that its supply agreements with marketing entities typically hold the marketer solely liable for any violations of DPCO provisions and associated penalties. The total impact on the parties is ₹52,74,68,193, which includes an overcharging amount of ₹18,94,80,649 for batches manufactured between December 2017 and August 2024, a penalty of ₹18,94,80,649 (100% of the overcharged amount), and an interest amount of ₹14,85,06,895 up to October 30, 2026. The company emphasized that the primary responsibility to respond to this notice lies with Hetero Healthcare Limited.
The company received this demand notice on October 15, 2026, at 11:05 A.M.
What to do with a filing like this
Akums Drugs and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under regulatory impact. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Akums Drugs and Pharmaceuticals Limited. Read the original for the full detail.